![]() Patients predisposed to active bleeding including thrombocytopenia, peptic ulcer disease, cerebrovascular disorders, haemorrhagic blood disorders, bacterial endocarditis, severe hypertension, oesophageal varices.Potentially Fatal: Heparin-induced thrombocytopenia with or without thrombosis bleeding.Hypersensitivity reactions include urticaria, conjunctivitis, rhinitis, asthma, angioedema and anaphylactic shock. Slight fever, headache, chills, nausea, vomiting, constipation, epistaxis, bruising, slight haematuria, skin necrosis (SC inj), osteoporosis, alopecia.Unlabeled uses: Adjunct in therapy of coronary occlusion with acute MI, prevention of left ventricular thrombi and CVA post-MI, prevention of cerebral thrombosis in the evolving CVA.Prevention of clotting in blood samples and heparin lock sets and during dialysis procedures.Treatment of atrial fibrillation with embolization.Prevention and treatment of venous thrombosis and pulmonary embolism.It may reduce the activity of ATIII at very high doses. This inhibits the conversion of prothrombin to thrombin and fibrinogen to fibrin. Heparin increases the inhibitory action of antithrombin III (AT III) on clotting factors XIIa, XIa, IXa, Xa and thrombin. ![]()
0 Comments
Leave a Reply. |